Effect of royal jelly on serum lipids in experimental animals and humans with atherosclerosis.
The primary objective of this review was to assess the size and consistency of Royal Jelly (RJ) effect on serum lipids in experimental animals and humans. The data from animal studies were pooled, where possible, and statistically evaluated by Student's t-test. Meta-analysis was used for the evaluation of human trials. It was found that RJ significantly decreased serum and liver total lipids and cholesterol levels in rats and rabbits and also retarded the formation of atheromas in the aorta of rabbits fed a hyperlipemic diet. Meta-analysis of the controlled human trials of RJ to reduce hyperlipidemia showed a significant reduction in total serum lipids and cholesterol levels and normalization of HDL and LDL as determined from decrease in beta/alpha lipoproteins. The best available evidence suggests that RJ at approximately 50 to 100 mg per day, decreased total serum cholesterol levels by about 14%, and total serum lipids by about 10% in the group of patients studied.
Vittek
J
J
Department of Medicine, New York Medical College, Valhalla 10595, USA.
D000818:Animals; D001161:Arteriosclerosis / Q000188:drug therapy / Q000503:physiopathology*; D002784:Cholesterol / Q000097:blood / Q000378:metabolism; D005227:Fatty Acids / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D008055:Lipids / Q000097:blood*; D008099:Liver / Q000378:metabolism; D011817:Rabbits; D051381:Rats; D000099219:Royal Jelly
D002784:Cholesterol; D005227:Fatty Acids; D000960:Hypolipidemic Agents; D008055:Lipids; D000099219:Royal Jelly